StockData
Retension Pharmaceuticals, Inc. logo

Retension Pharmaceuticals, Inc. (RTSN) stock

RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$13.89+2.48 (+21.74%)

Close on Nov 18, 2026Market cap $11.22MP/E –Yield –

Retension Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$5.02M–
Q3 FY2025Sep 30, 2025$1.37M–

More Retension Pharmaceuticals figures

See a number that looks wrong?